Biodesix financials
$29.14−4.21%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M | $45.6M |
| Gross profit | $71.8M | $55.8M | $36.1M | $38.2M | $54.5M | $45.6M |
| Gross margin | 81.1% | 78.2% | 73.5% | 100.0% | 100.0% | 100.0% |
| Operating income | -$27.9M | -$34.5M | -$41.3M | -$50.6M | -$40.9M | -$22.9M |
| Net income | -$35.3M | -$42.9M | -$52.1M | -$65.4M | -$43.2M | -$31.4M |
| Net margin | −39.8% | −60.2% | −106.2% | −171.3% | −79.2% | −68.8% |
| Diluted EPS | $-4.67 | $-6.64 | $-12.80 | $-31.00 | $-31.60 | $-129.60 |
| EBITDA | -$22.1M | -$28.5M | -$38.0M | -$44.7M | -$37.8M | -$20.0M |
| Operating cash flow | -$23.3M | -$48.6M | -$22.9M | -$45.0M | -$29.8M | -$22.2M |
| Free cash flow | -$23.5M | -$51.9M | -$45.8M | -$48.3M | -$32.1M | -$24.1M |
| Diluted shares | 7.6M | 6.5M | 4.1M | 2.1M | 1.4M | 0.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.0M | $26.2M | $26.3M | $43.1M | $32.7M | $62.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $47.5M | $36.4M | $35.3M | $25.1M | $10.0M | $27.8M |
| Total assets | $87.5M | $97.2M | $99.1M | $92.9M | $76.1M | $121.1M |
| Total liabilities | $89.9M | $76.4M | $94.5M | $72.3M | $56.4M | $79.9M |
| Shareholders' equity | -$2.5M | $20.9M | $4.6M | $20.6M | $19.7M | $41.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology